摘要
目的 探讨孕激素联合宫腔镜治疗早期子宫内膜癌(EC)及不典型增生(EAH)患者的效果及复发情况。方法 选取保留生育功能的32例早期EC和58例EAH患者作为研究对象,均使用孕激素联合宫腔镜治疗,评估临床效果。同时收集所有患者的年龄、BMI指数、不孕史、病灶直径、病灶形态等临床资料,分析影响治疗后复发的相关因素。结果 90例EC及EAH患者经治疗后均达到完全缓解,其中27例出现治疗后复发,63例未出现复发,复发率为30.00%(27/90)。复发患者中有6例患者开展了分期手术,14例患者再次进行保守治疗后达缓解,7例患者仍在治疗中。BMI指数、病灶直径、使用促排卵药物是影响EC及EAH患者保留生育功能治疗后复发的单因素(P<0.05);logistic回归分析显示,BMI指数>25 kg/m^(2)、病灶直径>2 cm、使用促排卵药物是EC及EAH患者保留生育功能治疗后复发的危险因素(P<0.05)。结论 EC及EAH患者保留生育功能治疗后复发影响因素主要为BMI指数、病灶直径和使用促排卵药物,临床应加强对危险因素的监测,并针对性采取预防措施,降低复发率。
Objective To investigate the efficacy and recurrence rate of progesterone combined with hysteroscopy in the treatment of early endometrial cancer(EC)and atypical hyperplasia(EAH)patients.Methods 32 patients with early EC and 58 patients with EAH who retained fertility function were selected as the study subjects,both of whom were treated with progesterone combined with hysteroscopy to evaluate clinical efficacy.Simultaneously collect clinical data such as age,BMI index,infertility history,lesion diameter,lesion morphology,etc.from all patients,and analyze the relevant factors that affect recurrence after treatment.Results 90 patients with EC and EAH achieved complete remission after treatment,with 27 cases experiencing postoperative recurrence and 63 cases not experiencing recurrence.The recurrence rate was 30.00%(27/90).Among the recurrent patients,6 underwent staged surgery,14 received conservative treatment again and achieved remission,while 7 patients are still under treatment.BMI index,lesion diameter,and the use of ovulation promoting drugs were factors that affect the recurrence of EC and EAH patients after fertility preservation therapy(P<0.05);Logistic regression analysis showed that BMI index>25 kg/m^(2),lesion diameter>2 cm,and use of ovulation promoting drugs were risk factors for recurrence in EC and EAH patients after fertility preservation therapy(P<0.05).Conclusion The main factors affecting recurrence in EC and EAH patients after fertility preservation therapy are BMI index,lesion diameter,and use of ovulation promoting drugs.Clinical monitoring of risk factors should be strengthened,and targeted preventive measures should be taken to reduce the recurrence rate.
作者
岳红
李静
YUE Hong;LI Jing(Hanzhong Central Hospital,Hanzhong 723000)
出处
《实用癌症杂志》
2023年第11期1903-1906,共4页
The Practical Journal of Cancer
关键词
子宫内膜癌
不典型增生
孕激素
宫腔镜
复发
Endometrial carcinoma
Atypical hyperplasia
Progesterone
Hysteroscopy
Recrudescence
